吡哆醛异烟酰肼 T5314

Product Introduction
Bioactivity


英文名: pyridoxal isonicotinoyl hydrazone

描述: pyridoxal isonicotinoyl hydrazone (PIH) 是亲脂的三价铁螯合剂，具有高铁螯合特性。

体外活性: After a 60-minute reincubation of 59Fe-labeled reticulocytes with tris-hydroxamate deferoxamine (5 mmol/L), 3.5% of cellular 59Fe was released, although Pyridoxal isonicotinoyl hydrazone (PIH) at a 50-fold lower concentration (0.1 mmol/L) released 38.6% of cellular 59Fe [1]. In primary human hepatocytes and the human hepatocellular carcinoma cell line HepG2/C3A, PIH treatment decreases Fech protein levels, but not Fech mRNA levels; and PIH is detected after isoniazid treatment, with levels increasing further when exogenous vitamin B6 analogs are coadministered [2].

体内活性: Intraperitoneal administration of PIH to mice (5 mg/25 gm mouse/day) over 6 days decreased 59Fe levels in the liver, spleen, and kidney but not in the blood. After oral administration, PIH resulted in an eightfold increase in fecal Fe excretion and possibly some urinary excretion of Fe [1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 28.63 mg/mL (100 mM)


关键字: inhibit | pyridoxal isonicotinoyl hydrazone | Inhibitor

相关库: Drug Repurposing Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Ferroptosis Compound Library | NO PAINS Compound Library | Bioactive Compound Library

吡哆醛异烟酰肼 T5314信息由TargetMol中国为您提供，如您想了解更多关于吡哆醛异烟酰肼 T5314报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途